BC Innovations | Jan 15, 2015
Finance

Consortia cross-talk

There's no doubt that the consortium model is here to stay, but the challenge now is to avoid creating a bureaucracy of committees with duplicate missions and redundancies of effort. The answer might be a...
BioCentury | May 27, 2013
Finance

Demand disequilibrium

BioCentury's 11th annual European Iceberg survey sees funding demand continue to fall for a shrinking number of public clinical-stage biotechs in Europe, while the capital demanded by the growing cadre of venture biotechs continues to...
BioCentury | Mar 4, 2013
Finance

EdRIP's exit mantra

As Edmond de Rothschild Investment Partners begins its second decade, it is moving to increase its footprint outside of Europe. With 18 life science exits since its inception in 2002, EdRIP believes its ability to...
BC Week In Review | Dec 24, 2012
Company News

ExonHit, InGen BioSciences deal

ExonHit completed its acquisition of in vitro diagnostic company InGen. The resulting company, Daixonhit, will continue to trade on Euronext under the symbol "ALEHT" (see BioCentury, Nov. 12). ExonHit S.A. (Euronext:ALEHT), Paris, France   InGen...
BC Week In Review | Dec 3, 2012
Financial News

ExonHit completes private placement

ExonHit S.A. (Euronext:ALEHT), Paris, France   Business: Neurology, Cancer, Ophthalmic   Date completed: 11/29/12   Type: Private placement   Raised: €1.7 million ($2.2 million)   Shares: 2.2 million   Price: €0.75   Shares after offering:...
BC Week In Review | Nov 12, 2012
Financial News

ExonHit completes private placement

ExonHit S.A. (Euronext:ALEHT), Paris, France   Business: Neurology, Cancer, Ophthalmic   Date completed: 11/7/12   Type: Private placement   Raised: €4.4 million ($5.6 million)   Shares: 5.8 million   Price: €0.75   Shares after offering:...
BC Week In Review | Nov 12, 2012
Company News

ExonHit, InGen BioSciences deal

ExonHit will acquire in vitro diagnostic company InGen for €18 million ($23 million) in a cash and stock deal. The resulting company will be named Diaxonhit. ExonHit will pay €8 million ($10.2 million) in cash...
BioCentury | Sep 10, 2012
Emerging Company Profile

Putting a Lid on PDE-4

Efforts to directly inhibit phosphodiesterase-4 's active site to treat neurological indications have failed due to dose-limiting toxicities. Tetra Discovery Partners LLC is trying to take side effects out of the equation with allosteric inhibitors...
BC Week In Review | Jul 23, 2012
Clinical News

AclarusDx: Completed enrollment

Exonhit completed enrollment of 600 patients complaining of cognitive disorders or memory impairment in the French DIALOG trial evaluating AclarusDx. The product has CE Mark approval and is available in France. ExonHit S.A. (Euronext:ALEHT), Paris,...
BC Week In Review | Jul 23, 2012
Clinical News

AclarusDx: Pilot trial completed enrollment

Exonhit completed enrollment of 160 newly referred patients with memory impairment in a U.S. pilot trial evaluating AclarusDx. The product has CE Mark approval and is available in France. ExonHit S.A. (Euronext:ALEHT), Paris, France  ...
Items per page:
1 - 10 of 168
BC Innovations | Jan 15, 2015
Finance

Consortia cross-talk

There's no doubt that the consortium model is here to stay, but the challenge now is to avoid creating a bureaucracy of committees with duplicate missions and redundancies of effort. The answer might be a...
BioCentury | May 27, 2013
Finance

Demand disequilibrium

BioCentury's 11th annual European Iceberg survey sees funding demand continue to fall for a shrinking number of public clinical-stage biotechs in Europe, while the capital demanded by the growing cadre of venture biotechs continues to...
BioCentury | Mar 4, 2013
Finance

EdRIP's exit mantra

As Edmond de Rothschild Investment Partners begins its second decade, it is moving to increase its footprint outside of Europe. With 18 life science exits since its inception in 2002, EdRIP believes its ability to...
BC Week In Review | Dec 24, 2012
Company News

ExonHit, InGen BioSciences deal

ExonHit completed its acquisition of in vitro diagnostic company InGen. The resulting company, Daixonhit, will continue to trade on Euronext under the symbol "ALEHT" (see BioCentury, Nov. 12). ExonHit S.A. (Euronext:ALEHT), Paris, France   InGen...
BC Week In Review | Dec 3, 2012
Financial News

ExonHit completes private placement

ExonHit S.A. (Euronext:ALEHT), Paris, France   Business: Neurology, Cancer, Ophthalmic   Date completed: 11/29/12   Type: Private placement   Raised: €1.7 million ($2.2 million)   Shares: 2.2 million   Price: €0.75   Shares after offering:...
BC Week In Review | Nov 12, 2012
Financial News

ExonHit completes private placement

ExonHit S.A. (Euronext:ALEHT), Paris, France   Business: Neurology, Cancer, Ophthalmic   Date completed: 11/7/12   Type: Private placement   Raised: €4.4 million ($5.6 million)   Shares: 5.8 million   Price: €0.75   Shares after offering:...
BC Week In Review | Nov 12, 2012
Company News

ExonHit, InGen BioSciences deal

ExonHit will acquire in vitro diagnostic company InGen for €18 million ($23 million) in a cash and stock deal. The resulting company will be named Diaxonhit. ExonHit will pay €8 million ($10.2 million) in cash...
BioCentury | Sep 10, 2012
Emerging Company Profile

Putting a Lid on PDE-4

Efforts to directly inhibit phosphodiesterase-4 's active site to treat neurological indications have failed due to dose-limiting toxicities. Tetra Discovery Partners LLC is trying to take side effects out of the equation with allosteric inhibitors...
BC Week In Review | Jul 23, 2012
Clinical News

AclarusDx: Completed enrollment

Exonhit completed enrollment of 600 patients complaining of cognitive disorders or memory impairment in the French DIALOG trial evaluating AclarusDx. The product has CE Mark approval and is available in France. ExonHit S.A. (Euronext:ALEHT), Paris,...
BC Week In Review | Jul 23, 2012
Clinical News

AclarusDx: Pilot trial completed enrollment

Exonhit completed enrollment of 160 newly referred patients with memory impairment in a U.S. pilot trial evaluating AclarusDx. The product has CE Mark approval and is available in France. ExonHit S.A. (Euronext:ALEHT), Paris, France  ...
Items per page:
1 - 10 of 168